REG - Arecor Therapeutics - Arecor sells rights to non-Ogluo® products

Arecor TherapeuticsAnnouncement

08/05/2025 07:01

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250508:nRSH7825Ha&default-theme=true

RNS Number : 7825H  Arecor Therapeutics PLC  08 May 2025

Arecor Therapeutics plc

("Arecor" or the "Company")

 

ARECOR SELLS RIGHTS TO NON-OGLUO® PRODUCTS FROM TETRIS PHARMA PORTFOLIO TO
ASPIRE PHARMA

 

Cambridge, UK, 8th May 2025: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company advancing today's therapies to enable healthier
lives, today announces the sale of rights to certain non-Ogluo® products from
the portfolio of its Tetris Pharma subsidiary to Aspire Pharma Limited
("Aspire").

 

Under the terms of the agreement, Arecor will receive a cash payment of £0.5
million from Aspire in return for both the UK distribution rights to the
products and the transfer of existing inventory.  There is no separate
financial information available in relation to the rights of the non-Ogluo®
products being sold. The Board intends to use the proceeds of the Transaction
for working capital purposes.

 

This agreement is part of the orderly cessation of Tetris Pharma operations,
as announced in January 2025, and the Company's strategic focus on areas which
best leverage its platform and resources to deliver transformational value
opportunities.

 

 

For more information, please contact:

 

 Arecor Therapeutics plc                                 www.arecor.com
 Dr Sarah Howell, Chief Executive Officer                Tel: +44 (0) 1223 426060

                                                         Email: info@arecor.com (mailto:info@arecor.com)
 David Ellam, Chief Financial Officer                    Tel: +44 (0) 1223 426060

                                                         Email: info@arecor.com (mailto:info@arecor.com)

 Singer Capital Markets Advisory LLP (NOMAD and Broker)
 Phil Davies, Sam Butcher                                Tel: +44 (0) 20 7496 3000

 ICR Healthcare
 Chris Gardner, David Daley, Lindsey Neville             Tel: +44 (0) 20 3709 5700

                                                         Email: arecor@icrhealthcare.com (mailto:arecor@icrhealthcare.com)

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio. For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUBSKRVSUVRAR